Dual-Action Antibody Cuts Asthma Attacks in Mid-Stage Trial
An investigational biologic targeting both TSLP and IL-13 reduced asthma exacerbations by over half in a phase II trial. The highest dose of lunsekimig also improved lung function and patient-reported outcomes, with effects more pronounced in severe cases. Researchers caution that head-to-head comparisons with existing biologics are still needed to confirm its advantage.
The AIRCULES study enrolled adults with moderate-to-severe asthma who required medium-to-high doses of inhaled corticosteroids. Monthly injections of the 300 mg dose lowered exacerbation frequency by 55.3% over 48 weeks, while also producing quick and durable improvements in lung function and patient-reported quality of life. The strongest responses appeared in those with more frequent attacks.
Researchers are investigating whether blocking an upstream inflammatory trigger alongside a downstream mediator yields additive or synergistic benefits compared with existing single-pathway biologics. Beyond asthma, lunsekimig is advancing into phase III trials for chronic obstructive pulmonary disease, and additional phase II studies are assessing its use in high-risk asthma.
If lunsekimig's dual-targeting strategy proves superior in future head-to-head comparisons, it could provide a valuable alternative for asthma patients who only partially respond to current therapies. This may translate into fewer severe attacks and reduced hospitalizations for those with difficult-to-control disease. However, pricing and insurance coverage could shape its practical availability, and without direct comparative data, its precise role in treatment algorithms remains uncertain.